# NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

> **NCT05262673** · PHASE1 · UNKNOWN · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 10 (estimated)

## Conditions studied

- B-Cell Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** Antigen-specific T cells CART/CTL and DCvac

## Key facts

- **NCT ID:** NCT05262673
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2022-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05262673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05262673, "NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05262673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*